New groups of hypolipidemic medications based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1

Hypolipidemic therapy is one of the essential components for management patients with cardiovascular diseases (CVD). In this regard, main task modern research to find new targets creating additional effective groups hypolipidemic medications. Canadian and French led by N. Seidah M. Abifadel discovered a enzyme — proprotein convertase subtilisin-kexin type 9 (PCSK9) in 2003. It turned out play an important role lipid metabolism later. The mechanism action PCSK9 regulate density low-density lipoprotein receptors (LDLR) cell membrane hepatocytes. Increased activity accelerates degradation LDL significantly, leads increase concentration atherogenic classes lipoproteins (LDL). contrast, reduced accompanied decrease concentrations risk developing atherosclerosis CVD. second recently less studied protearogenic inflammatory processes atherosclerotic plaque. Considering adverse contribution development progression CVD, researchers was develop medications that inhibit THIS enzyme. Several target stages biosynthesis function have been developed now. article, we will focus on details discussing mechanisms effectiveness following medications: anti-PCSK9 monoclonal antibodies (alirocumab, evolocumab), small interfering ribonucleic acids (incliciran), antisense nucleotides.